Cure My Disease

Don't miss your cure!

 Log in / Sign up

38,000 arthritis patients tracked: is abatacept safe Long-Term?

NCT ID NCT05421442

Completed Knowledge-focused Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study looked at the safety of the arthritis drug abatacept in over 38,000 people with rheumatoid or psoriatic arthritis in Denmark. Researchers used a national health registry to track rates of cancers and other side effects. The goal was to better understand the drug's real-world safety profile.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
abatacept
What this could lead to
If successful, this study could provide a clearer picture of the long-term safety of abatacept for arthritis patients.
What could go wrong
This is an observational study using registry data, not a controlled trial. It cannot prove cause and effect, and results may not apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PSORIATIC ARTHRITIS (PSA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm psoriatic arthritis rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PSORIATIC ARTHRITIS (PSA) RHEUMATOID ARTHRITIS (RA)

Contacts and locations

Locations

  • Local Institution - 0001

    Lawrenceville, New Jersey, 08543, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.